Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss

Next Previous
Trial Profile

A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Serabelisib (Primary)
  • Indications Adenocarcinoma; Clear cell sarcoma; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Transitional cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Faeth Therapeutics

Most Recent Events

  • 30 Apr 2026 Status changed to discontinued due to program prioritization.
  • 06 Oct 2025 Status changed from active, no longer recruiting to completed.
  • 27 Feb 2025 Planned End Date changed from 1 Sep 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top